Navigation Links
The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
Date:3/14/2008

t attack and re-treatment of a diseased lesion (ischemia-driven target lesion revascularization) in the ABSORB trial. Abbott's bioabsorbable everolimus eluting stent also demonstrated 100 percent procedural success and 94 percent device success in the ABSORB trial.

"Patients and physicians like the idea of a stent that does its job and is then absorbed away," said John A. Ormiston, M.B., Ch.B., cardiologist at Auckland City Hospital, in Auckland, New Zealand and principal investigator in the ABSORB trial. "Abbott's bioabsorbable stent has the potential to hold an artery open long enough for healing to occur, and we would expect an artery that is healed to function as it did before it became diseased."

Abbott is the only company with a fully bioabsorbable drug eluting coronary stent in clinical trials. Abbotts bioabsorbable everolimus eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbotts bioabsorbable stent is designed to restore blood flow in clogged coronary arteries, and to provide mechanical support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott's bioabsorbable drug eluting stent system is a great example of scientific innovation leading to a breakthrough treatment for heart disease that has the potential to improve patients' lives," said John M. Capek, Ph.D., executive vice president of medical devices, Abbott. "We look forward to continuing to evaluate the safety and effectiveness of our bioabsorbable stent platform in additional patients in the coming months."


'/>"/>

Contact: Karin Bauer
408-845-3887
Abbott Vascular
Source:Eurekalert

Page: 1 2

Related biology news :

1. World-leading journal publishes special issue on UN/GA
2. DOE publishes update of plan: Facilities for the Future of Science: A 20-Year Outlook
3. University biologist publishes book on bird speciation
4. NHLBI issues first US von Willebrand Disease clinical practice guidelines
5. Iowa State researchers help piece together the corn genomes first draft
6. First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills
7. Map is first to track global human influences on ocean ecosystems
8. First map of threats to marine ecosystems shows all the worlds oceans are affected
9. First datasets for national biomass and carbon dataset now available
10. Stanford researchers make first direct observation of 3-D molecule folding in real time
11. Genes and environment interact in first graders to predict physical but not social aggression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... common genetic variants related to a risk factor for ... in the journal Nature Genetics identifies variants ... influence the QT interval measured on the electrocardiogram (EKG) ... help to prevent sudden cardiac death and arrhythmia by ...
... skin cells know when to proliferate and at what ... Journal of Cell Biology , Nguan Soon Tan ... called PPARβ/δ to make sure overlying epithelial cells don,t ... different cell types are critical to maintain the skin ...
... desk and suddenly your heart is beating in overdrive ... It is a shocking, uncomfortable and frightening sensation. ... sudden cardiac death or SCD, a condition that accounts ... are now closer to understanding what causes SCD and ...
Cached Biology News:Common gene variants influence risk factor for sudden cardiac death 2Common gene variants influence risk factor for sudden cardiac death 3Time (and PPAR-beta/delta) heals all wounds 2Time (and PPAR-beta/delta) heals all wounds 3Ten genes identified in connection with sudden cardiac death 2
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
(Date:12/19/2014)... -- Bina Technologies, Inc. (Bina, Redwood City, ... been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).  ... that provides a big data platform for centralized management ... the academic and translational research markets.  Bina will be ... to focus on development of their innovative genomic analysis ...
(Date:12/19/2014)... , Dec. 19, 2014 Research and Markets ... addition of the "Technology Innovations in Smart ... http://photos.prnewswire.com/prnh/20130307/600769 ... Smart Fabrics" offers a detailed assessment on technological ... Key Findings: 1. The Smart ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... could help farmers worldwide, research suggests. Scientists have developed ... cows but has no effect on their health to ... the vaccine by inserting key genetic material from a vaccine ... be injected into cattle, where it would continue to thrive ...
... Barron, Rice University,s Charles W. Duncan, Jr. -- Welch ... the winner of the prestigious 2011 World Technology Award ... Technology Summit and Awards gala at the United Nations ... of nanotechnology to fundamental problems in energy and health ...
... Oct. 27, 2011 Halozyme Therapeutics, Inc. ... and commercializing products targeting the extracellular matrix ... today announced clinical trial results related to Halozyme,s clinical ... at the 2011 EORTC-NCI-ASCO Annual Meeting on "Molecular Markers ...
Cached Biology Technology:Rice's Barron wins World Technology Award for Materials 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: